Press release
Investigation announced for Investors in shares of Atreca, Inc. (NASDAQ: BCEL)
An investigation for investors in Atreca, Inc. (NASDAQ: BCEL) shares over potential securities laws violations by Atreca, Inc.
Investors who purchased shares of Atreca, Inc. (NASDAQ: BCEL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Atreca, Inc. (NASDAQ: BCEL regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Redwood City, CA based Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types.
On or around June 19, 2019, Atreca, Inc. conducted its initial public offering ("IPO"), issuing 7,350,000 shares of common stock priced at $17.00 per share.
Shares of Atreca, Inc. reached as high as $29.35 per share on March 4, 2020.
Theon, on March 11, 2020, Atreca, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2019. Among other results, Atreca, Inc. reported fourth quarter GAAP earnings per share of -$0.72, falling $0.03 short of consensus estimates.
Shares of Atreca, Inc. (NASDAQ: BCEL) declined to as low as $10.88 per share on March 18, 2020.
Those who purchased shares of Atreca, Inc. (NASDAQ: BCEL) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Atreca, Inc. (NASDAQ: BCEL) here
News-ID: 1974431 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Atreca
Neuroendocrine Tumour Market is Expected to Show a Healthy Growth Rate During th …
DelveInsight's "Neuroendocrine Tumours Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Neuroendocrine Tumours, historical and forecasted epidemiology as well as the Neuroendocrine Tumours market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Download Sample Report to know more @https://www.delveinsight.com/sample-request/neuroendocrine-tumours-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Neuroendocrine Tumour Overview
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most…
Acral Lentiginous Melanoma Market is Expected to Show a Healthy Growth Rate Duri …
DelveInsight's "Acral lentiginous melanoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Acral lentiginous melanoma, historical and forecasted epidemiology as well as the Acral lentiginous melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Download Sample Report to know more @https://www.delveinsight.com/sample-request/acral-lentiginous-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Acral Lentiginous Melanoma Overview
Acral lentiginous melanoma is an aggressive type of skin cancer. Melanoma is a group…
Immune Repertoire Sequencing Market 2023 | Futuristic Trends- Juno Therapeutics, …
The Immune Repertoire Sequencing report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research.
The Immune Repertoire Sequencing research report recognizes and…
Immune Repertoire Sequencing Market - Thermo Fisher Scientific, Inc., Illumina I …
Immune repertoire refers to sub-type protein that an organism’s immune system creates. Immune systems in vertebrates have six key types of proteins- two immunoglobulin and four T cell receptors. Immune repertoire sequencing enables researchers and scientists to examine and understand adaptive immune-mediated diseases. Immune repertoire sequencing is also widely applicable in biomarker discovery, infectious disease research, asthma and allergy research, and cancer immunotherapy.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1517
…
Immune Repertoire Sequencing Market is Thriving Worldwide, Emerging Trends and T …
The global immune repertoire sequencing market is expected to reach USD 209.7 million by 2028 at a CAGR of 8.4% during the forecast period.
Europe is expected to achieve the highest growth in the forecast period. The increased funding by the government alongside rising healthcare expenditure is expected to expand the size of the market in the region. Asia-Pacific region is also predicted to show immense growth of the market in…
Immune Repertoire Sequencing Market to Surpass USD 209.7 million by 2028 | Adapt …
The global immune repertoire sequencing market is expected to reach USD 209.7 million by 2028 at a CAGR of 8.4% during the forecast period.
In terms of region, North America is expected to hold a vast share of the market. Presence of a vast number of prominent players alongside growing attention towards novel technology for immune repertoire sequencing remains the key factor behind the growth of the market in the region.…
